IBRX
ImmunityBio Inc

19,797
Mkt Cap
$1.95B
Volume
9.89M
52W High
$4.27
52W Low
$1.83
PE Ratio
-4.71
IBRX Fundamentals
Price
$1.98
Prev Close
$1.98
Open
$1.98
50D MA
$2.20
Beta
2.06
Avg. Volume
9.71M
EPS (Annual)
-$0.6189
P/B
-3.72
Rev/Employee
$21,683.82
Loading...
Loading...
News
all
press releases
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Up 23.1% in December
ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 109,024,436 shares, an...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
2025 Greatest Hits: The Most Popular Articles Of The Past Year And A Look Ahead
2025 Greatest Hits: The Most Popular Articles Of The Past Year And A Look Ahead One year ago, when looking at the 20 most popular stories of 2024, we said that "while 2024 had a seemingly endless...
Zero Hedge·13h ago
News Placeholder
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
Zacks·3d ago
News Placeholder
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of 100 Most Influential People in Oncology in 2025
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of The 100 Most Influential People in...
Business Wire·3d ago
News Placeholder
ImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - Here's What Happened
ImmunityBio (NASDAQ:IBRX) Trading Down 5.1% - Here's Why...
MarketBeat·9d ago
News Placeholder
ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9% - Should You Buy?
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9% - Should You Buy...
MarketBeat·9d ago
News Placeholder
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Zacks·14d ago
News Placeholder
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study
ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder cancer patients.read more...
Benzinga·16d ago
News Placeholder
ANKTIVA with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Gurin (BCG) demonstrates efficacy...
Business Wire·16d ago
News Placeholder
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat...
MarketBeat·19d ago
<
1
2
...
>

Latest IBRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.